Goodwin, a leading Global 50 law firm, announced today that Catherine McCarty has joined Goodwin’s Life Sciences Practice as a partner in Boston. McCarty specializes in intellectual property relating to pharmaceuticals and general chemistry matters, including small molecule drugs.
“We have developed one of the premiere life sciences practices in the industry by offering clients best-in-class capabilities in corporate, licensing, intellectual property and regulatory matters,” said Mitch Bloom, chair of Goodwin’s Life Sciences Practice. “Cathy is an extremely well-regarded strategic patent adviser with strong technical skills, deep industry expertise, and an established network. We are very excited to welcome her to our firm as we continue to grow our life sciences practice domestically and internationally.”
McCarty works with life sciences companies to protect innovations and procure intellectual property. She advises public and private companies, venture funds and entities that invest in, or evaluate, pharmaceutical and life science companies and technologies. McCarty also handles a diverse range of initiatives for clients including designing and managing worldwide patent estates on drug candidates, evaluating competitive landscapes to determine patentability and freedom to operate, formulating intellectual property strategy for emerging companies, performing intellectual property due diligence for investors, and advising on license agreements, collaborations and regulatory issues. She also has worked on various litigation matters involving pharmaceutical and chemical products.
McCarty joins Goodwin from Lando & Anastasi LLP, where she was a partner. She earned her J.D. from Harvard Law School, M.S. in Chemistry from Yale University, and B.S. in Chemistry with honors from Indiana University. McCarty is registered to practice before the U.S. Patent and Trademark Office. She can be reached at cmccarty@goodwinlaw.com or 617.570.1129.
Goodwin’s Life Sciences Practice is deeply experienced in corporate governance, financing and M&A transactions, collaborations and licensing, regulatory matters, and intellectual property law. It was recently named “Practice Group of the Year” by Law360, recognized for being “a top choice for high-profile pharmaceutical clients, particularly in licensing deals, mergers and acquisitions, and initial public offerings.” The firm has been consistently recognized by U.S. News and World Report - Best Lawyers as “Biotech Firm of Year,” including in 2017.